Sector News

Bayer Corporation Names Steven Immergut to Vice President, Head of Pharmaceutical Communications

January 8, 2015
Life sciences

/PRNewswire/ – Bayer Corporation today announced the appointment of Steven Immergut to a newly created senior position leading communications for the company’s pharmaceutical business in the United States.

Immergut spent the last three years in senior roles at the U.S. Food and Drug Administration (FDA), most recently as Acting Associate Commissioner for External Affairs.  In his new role as Vice President and Head of Communications, Bayer HealthCare Pharmaceuticals, Immergut will be responsible for developing and executing external and internal communication strategies for Bayer’s pharmaceutical portfolio in the United States.  He will be based in Washington, D.C., with regular travel to Whippany, N.J.  

Immergut will report directly to Raymond F. Kerins, Jr., Senior Vice President and Head of Communications, Government Relations and Policy for Bayer Corporation, and will serve on the U.S. Communications, Government Relations and Policy Leadership Team.

“I am delighted to have Steven join the Bayer team as we continue to raise Bayer’s profile in the United States and advance our goal of  ‘Science For A Better Life,’ ” Kerins said.  “Steven’s unparalleled healthcare communications experience, together with his knowledge of the regulatory environment and public health expertise, will be tremendous assets to Bayer.  I look forward to working with him closely as we advance communications about our pharmaceutical products to key audiences here in the United States, Bayer’s largest and fastest growing market.”

Throughout his extensive career, Immergut has designed, managed and executed strategic communications initiatives on behalf of organizations across the healthcare sector, including the federal government, biopharmaceutical and medical device companies, associations, healthcare providers and patient groups.

Immergut joins Bayer after serving as Acting Associate Commissioner for External Affairs at the FDA, where he directed communications and media on a wide range of regulatory and educational activities and issues, enhanced stakeholder relationships, and helped FDA continue to transform its website and blog into meaningful channels of communication.  For two years he served as Assistant Commissioner for Media Affairs, leading the agency’s interactions with the news media.  Immediately prior to his FDA service, Immergut managed government and private sector health communications activities for the management consulting firm Booz Allen Hamilton.  He previously directed the Washington, D.C. healthcare practice of Hill+Knowlton Strategies, a global public relations company, and for more than a decade provided communications counsel to blue chip pharmaceutical and medical device companies.  Earlier in his career, Immergut consulted for the U.S. Agency for International Development (USAID) in Latin America, where he worked on groundbreaking public health social marketing programs in HIV/AIDS, reproductive health and diarrheal diseases.  Immergut received his Master of Public Health from George Washington University and his B.S. degree in Marketing Management from Syracuse University. 

“I am honored to join the talented team at Bayer to lead communications for its exciting pharmaceutical portfolio in the United States at such a critical time of growth for the company,” Immergut said.  “A strong commitment to quality science as the foundation for innovation and getting treatments to patients who need them will help further set Bayer apart as it continues to advance in life sciences.”

Source: Bayer Corporation

 

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend